Shaw J H, Douglas R, Wilson T
Department of Surgery, Auckland Hospital, New Zealand.
Aust N Z J Surg. 1988 Aug;58(8):657-9. doi: 10.1111/j.1445-2197.1988.tb07578.x.
A recent advance in semipermanent vascular access has been the development of the totally implanted Portacath atrial catheter. The outcome of 100 sequential insertions of atrial catheters, 61 of which were Hickman catheters and 39 Portacaths, has been retrospectively reviewed in order to determine differences in clinical performance between these two types. The majority (90%) of the patients were from haematology or oncology wards. The incidence of complications was 66% for Hickman catheters and 46% for Portacaths. Local sepsis developed in 34% of the Hickman catheters and line-related septicaemia in 21%. The frequency of local sepsis and septicaemia following Portacath insertion was 31% and 3% respectively. Complications necessitated the removal of 33% of the Hickman catheters and 15% of Portacaths. The mean duration of insertion was 10 weeks for Hickman catheters and 24 weeks for Portacaths. It is concluded that the Portacath is less frequently complicated by sepsis and offers significant advantages for those patients in whom it is used.
半永久性血管通路的一项最新进展是全植入式Portacath心房导管的研发。为了确定这两种类型心房导管在临床表现上的差异，对100例连续植入心房导管的病例进行了回顾性研究，其中61例为希克曼导管，39例为Portacath导管。大多数（90%）患者来自血液科或肿瘤科病房。希克曼导管的并发症发生率为66%，Portacath导管为46%。34%的希克曼导管发生局部感染，21%发生与导管相关的败血症。Portacath导管植入后局部感染和败血症的发生率分别为31%和3%。并发症导致33%的希克曼导管和15%的Portacath导管被拔除。希克曼导管的平均植入时间为10周，Portacath导管为24周。结论是，Portacath导管发生败血症的并发症较少，对使用它的患者具有显著优势。
